RTI Surgical® Announces Cigna’s Positive Medical Coverage Policy for Minimally Invasive SI Joint Fusion Surgery Using the ...
December 16 2019 - 7:05AM
RTI Surgical Holdings, Inc. (Nasdaq: RTIX), a global surgical
implant company, today announced that Cigna Corporation, a global
health service company, issued a positive medical coverage policy
for minimally invasive sacroiliac (SI) joint fusion under certain
medically necessary criteria. This policy covers the use of all
FDA-cleared implants placed across the SI joint and intended to
promote bone fusion, including the use of RTI’s
SImmetry® Sacroiliac Joint Fusion System. The SImmetry System
is a minimally invasive surgical solution that uses proprietary
decortication technology, bone grafting and threaded fixation to
facilitate bone fusion, providing an opportunity for long-term pain
relief.
“RTI is pleased with Cigna’s new coverage policy for minimally
invasive SI joint fusion procedures, including those completed with
our SImmetry System,” said Camille Farhat, President and CEO, RTI
Surgical. “Our clinical distinction for the SImmetry System
continues to strengthen, with interim results of the EVoluSIon
study for 148 patients at 12 months showing 71 percent of patients
with significant pain reduction, a 60 percent decrease in the
number of patients using opioids and 86 percent of patients
satisfied with their SImmetry System implant.”
Cigna, the fourth-largest medical insurance company in the U.S.
with nearly 15 million customers, made its new policy, “Lumbar
Fusion for Spinal Instability and Degenerative Disc Conditions,
Including Sacroiliac Fusion,” effective as of December 10, 2019,
which can be found here.
About RTI Surgical Holdings, Inc.
RTI Surgical is a leading global surgical implant company
providing surgeons with safe biologic, metal and synthetic
implants. Committed to delivering a higher standard, RTI’s implants
are used in sports medicine, general surgery, spine, orthopedic and
trauma procedures and are distributed in nearly 50 countries. RTI
has four manufacturing facilities throughout the U.S. and Europe.
RTI is accredited in the U.S. by the American Association of Tissue
Banks and is a member of AdvaMed. For more information, please
visit www.rtix.com. Connect with us
on LinkedIn and Twitter. Clinical cases are unique
and individual results may vary. Regulatory approvals vary by
country. Therefore, we kindly ask you to contact your RTI Surgical
regional leader regarding availability of specific products,
implants and/or instrumentation in your region.
Forward-Looking Statements
Portions of this document may constitute “forward-looking
statements” as defined by federal law. Although the company
believes any such statements are based on reasonable assumptions,
there is no assurance that actual outcomes will not be materially
different. Any such statements are made in reliance on the “safe
harbor” protections provided under the Private Securities Reform
Act of 1995. Additional information about issues that could lead to
material changes in performance is contained in the company’s
annual and quarterly reports filed with the Securities and Exchange
Commission.
Steven Cohen Media Contact scohen@rtix.com +1
847 648 0861
Molly Poarch Investor Contact mpoarch@rtix.com
+1 224 287 2661
RTI Surgical (NASDAQ:RTIX)
Historical Stock Chart
From Aug 2024 to Sep 2024
RTI Surgical (NASDAQ:RTIX)
Historical Stock Chart
From Sep 2023 to Sep 2024